In 2006 Novartis opened its state-of-the-art Animal Health's Center for Aqua Research and Development facility in Victoria, Prince Edward Island. The goal of the PEI R&D facility is to bring new and innovative vaccine solutions for preventing and controlling disease-causing pathogens in farmed fish species, including salmon, carp, marine fish, tilapia, and catfish.
According to Novartis Canada CEO Grant Roberts, "By expanding our facilities, we are supporting aquaculture through continued in-depth study of health solutions for the challenges that face both currently cultured and emerging species of fish." Roberts sees a number of advantages to the company's investments in Prince Edward Island: "PEI has quality marine resources and top research institutes that make it attractive for a company like Novartis to maintain one of our five global research and development centers here," he concludes. "We look forward to continuing the great partnerships in place here."